
1. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub
2021 Oct 13.

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 
diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective
cohort study.

Nomah DK(1), Reyes-Urueña J(2), Díaz Y(3), Moreno S(3), Aceiton J(3), Bruguera
A(4), Vivanco-Hidalgo RM(5), Llibre JM(6), Domingo P(7), Falcó V(8), Imaz A(9),
Cortés C(10), Force L(11), Letang E(12), Vilaró I(13), Casabona J(4), Miro
JM(14); PISCIS study group.

Collaborators: Muntada E, Esteve A, Riera M, Navarro G, Knobel H, Mallolas J,
Podzamczer D, Curran A, Burgos J, Mateo MG, Gutierrez MDM, Murillas J, Homar F,
Fernández-Montero JV, González E, Peraire J, Vidal F, Leon E, Masabeu À, Orti AJ,
Dalmau D, Jaen À, Deig E, De Lazzari E, Berrocal L, Fernandez G, Rodríguez L,
Gargoulas F, Vanrell T, Rubia JC, Vilà J, Martínez M, Morell B, Tamayo M, Palacio
J, Ambrosioni J, Laguno M, Martínez-Rebollar M, Blanco JL, Garcia F, Martínez E, 
Torres B, de la Mora L, Inciarte A, Ugarte A, Chivite I, González-Cordon A, Leal 
L, Jou A, Saumoy M, Silva A, Scévola S, Navarro J, Suanzes P, Mur I, Ribas MÀ,
Campins AA, Fanjul F, Leyes M, Peñaranda M, Martin ML, Vilchez HH, Calzado S,
Cervantes M, Amengual MJ, Navarro M, Payeras A, Cifuentes C, Villoslada A, Sorní 
P, Molero M, Abdulghani N, Comella T, Sola R, Vargas M, Viladés C, Martí A,
Barrufet P, Arbones L, Chamarro E, Cairó M, Martinez-Lacas X, Font R, Macorigh L.

Author information: 
(1)Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i
Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona,
Spain; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina
Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra,
Spain; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
(2)Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i
Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona,
Spain; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain; CIBER
Epidemiologia y Salud Pública, Barcelona, Spain. Electronic address:
jmreyes@iconcologia.net.
(3)Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i
Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona,
Spain; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain; CIBER
Epidemiologia y Salud Pública, Barcelona, Spain.
(4)Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i
Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona,
Spain; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina
Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra,
Spain; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain; CIBER
Epidemiologia y Salud Pública, Barcelona, Spain.
(5)Agència de Qualitat i Avaluació Sanitàries de Catalunya, Barcelona, Spain.
(6)Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
(7)Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
(8)Vall d'Hebron Research Institute, Hospital de Vall d'Hebron, Barcelona, Spain.
(9)Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute
(IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
(10)Hospital Moises Broggi-Consorci Sanitari Integral, L'Hospitalet de Llobregat,
Spain.
(11)Hospital de Mataró, Mataró, Spain.
(12)Hospital del Mar, Barcelona, Spain; ISGlobal, Barcelona Institute for Global 
Health, Hospital Clínic-University of Barcelona, Barcelona, Spain.
(13)Hospital de Vic, Vic, Spain.
(14)Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer,
University of Barcelona, Barcelona, Spain. Electronic address: jmmiro@ub.edu.

Comment in
    Lancet HIV. 2021 Nov;8(11):e661-e662.

BACKGROUND: Factors affecting outcomes of SARS-CoV-2 infection in people living
with HIV are unclear. We assessed the factors associated with SARS-CoV-2
diagnosis and severe outcomes among people living with HIV.
METHODS: We did a retrospective cohort study using data from the PISCIS cohort of
people with HIV in Catalonia (Spain) between March 1 and Dec 15, 2020. We linked 
PISCIS data with integrated health-care, clinical, and surveillance registries
through the Public Data Analysis for Health Research and Innovation Program of
Catalonia (PADRIS) to obtain data on SARS-CoV-2 diagnosis, chronic comorbidities,
as well as clinical and mortality outcomes. Participants were aged at least 16
years in care at 16 hospitals in Catalonia. Factors associated with SARS-CoV-2
diagnoses and severe outcomes were assessed using univariable and multivariable
Cox regression models. We estimated the effect of immunosuppression on severe
outcomes (hospital admission for >24 h with dyspnoea, tachypnoea, hypoxaemia,
asphyxia, or hyperventilation; or death) using Kaplan-Meier survival analysis.
FINDINGS: We linked 20 847 (72·8%) of 28 666 participants in the PISCIS cohort
with PADRIS data; 13 142 people had HIV. 749 (5·7%) people with HIV were
diagnosed with SARS-CoV-2: their median age was 43·5 years (IQR 37·0-52·7), 131
(17·5%) were female, and 618 (82·5%) were male. 103 people with HIV (13·8%) were 
hospitalised, seven (0·9%) admitted to intensive care, and 13 (1·7%) died.
SARS-CoV-2 diagnosis was more common among migrants (adjusted hazard ratio 1·55, 
95% CI 1·31-1·83), men who have sex with men (1·42, 1·09-1·86), and those with
four or more chronic comorbidities (1·46, 1·09-1·97). Age at least 75 years (5·2,
1·8-15·3), non-Spanish origin (2·1, 1·3-3·4), and neuropsychiatric (1·69,
1·07-2·69), autoimmune disease (1·92, 1·14-3·23), respiratory disease (1·84,
1·09-3·09), and metabolic disease (2·59, 1·59-4·23) chronic comorbidities were
associated with increased risk of severe outcomes. A Kaplan-Meier estimator
showed differences in the risk of severe outcomes according to CD4 cell count in 
patients with detectable HIV RNA (p=0·039) but no differences were observed in
patients with undetectable HIV RNA (p=0·15).
INTERPRETATION: People living with HIV with detectable HIV viraemia, chronic
comorbidities, and some subpopulations could be at increased risk of severe
outcomes from COVID-19. These groups should be prioritised in clinical management
and SARS-CoV-2 vaccination programmes.
FUNDING: Fundació "la Caixa".
TRANSLATIONS: For the Catalan, Spanish and Russian translations of the Summary
see Supplementary Materials section.

Copyright © 2021 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S2352-3018(21)00240-X 
PMCID: PMC8514194
PMID: 34655549  [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests JMM reports receiving a 
personal 80:20 research grant from Institut d'Investigacions Biomèdiques August
Pi I Sunyer, Barcelona, Spain, during 2017–21. EL reports receiving honoraria for
lectures and presentations from ViiV Healthcare, Gilead Sciences, and Jansen
Therapeutics; travel support for attending meetings from ViiV Healthcare and
Jansen Therapeutics; payments for participating in the data safety monitoring and
advisory board of ViiV Healthcare; being a full time employee of ViiV Healthcare 
since May 3, 2020; and payments made from Juan Rodés to the Spanish Government on
his behalf. PD reports that his institution received grants from Gilead Sciences,
Janssen-Cilag, and ViiV Healthcare; and he personally received honoraria from
Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, ViiV Healthcare, Roche, and 
Thera Technologies. AI reports that his institution received grants from Gilead
Sciences and Merck Sharp & Dohme; and he personally received consultation fees
from Gilead Sciences, ViiV Healthcare, and Thera Technologies; honoraria for
lectures and presentations from Gilead Sciences, Merck Sharp & Dohme, Jansen
Therapeutics, and ViiV Healthcare; and travel support for attending meetings from
Gilead Sciences, Jansen, and ViiV Healthcare. VF reports that his institution
received grants from Gilead Sciences, ViiV Healthcare, and Merck Sharp & Dohme;
and he personally received consultation fees from ViiV Healthcare; honoraria for 
lectures and presentations from ViiV Healthcare, Gilead Sciences, Jansen
Therapeutics, and Merck Sharp & Dohme; and travel support for attending meetings 
from Gilead Sciences. All other authors declare no competing interests.

